Healthcare Industry News: bone graft
News Release - March 15, 2011
K2M Receives CE Mark for RAVINE Lateral Access System & ALEUTIAN Lateral Interbody SystemLEESBURG, Va.--(Healthcare Sales & Marketing Network)-- K2M, Inc., the spinal device company developing innovative and simplified solutions for the treatment of complex spinal pathologies and procedures, today announced the RAVINE™ Lateral Access and ALEUTIAN® Lateral Interbody Systems received CE Mark clearance to expand the global presence of the company’s minimally invasive product offering.
RAVINE provides a dual flat blade platform for a true muscle splitting transpsoas approach. The system offers rigid fixation to the spine and an option for both a third and fourth blade. It represents an innovative design departure from the tubular retractors, while providing tremendous adaptability to both patient anatomy and surgeon technique.
ALEUTIAN Lateral is comprised of anatomically designed interbody implants made of PEEK material that are used in conjunction with the RAVINE Retractor. The implants feature radiolucent properties, which have the potential to increase visualization of bone graft while aiding in accurate fusion assessment. The bulleted nose allows for ease of insertion and the circumferential rings provide 360 degrees of grip to the endplates.
According to Mr. Colin Natali, Orthopedic Surgeon at the Royal London Hospital, “RAVINE is simple and easy to use. The retractor fixes to the vertebrae, as opposed to the operating table, and has a small footprint to potentially reduce the risk of surgical damage. It uses the anatomy of the muscle and the plexus to its advantage with the split and twist technique. The system evolved from the collaboration of surgeons and engineers working in unison to provide leading, rather than following, technology.”
“CE Mark clearance for RAVINE and ALEUTIAN Lateral expands the K2M minimally invasive product offering and fuels our rapid international growth,” stated Eric Major, K2M’s President and CEO. “These high profile next generation products reaffirm our commitment to becoming a leader in the global spine market.”
K2M, Inc. is an innovative spinal device company committed to the research, development, and commercialization of simplified solutions for the treatment of complex spinal pathologies and procedures. The company is recognized as a worldwide leader in providing unique technologies for the treatment of deformity, degenerative, trauma, and tumor spinal patients. K2M’s complete portfolio of next generation products includes: spinal stabilization systems, minimally invasive systems, and other advancing technologies, such as motion preservation, annular repair, and nucleus replacement. Additional information is available online at www.K2M.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.